Alkermes
ALKS · Pharmaceuticals
$43.63
1.2%Amneal Pharmaceuticals
AMRX · Pharmaceuticals
$20.38
0.5%The short version
- Amneal Pharmaceuticals is the larger business, with $3.0B of revenue in fiscal 2025 against $1.5B for Alkermes, about 2.0 times as much.
- Amneal Pharmaceuticals grew revenue faster (8.1%, against −5.3%).
- Alkermes kept more of each dollar of sales as operating profit (17.2% operating margin, against 13.1% operating margin).
- Alkermes turned more of its sales into free cash flow (32.6% FCF margin, against 8.9% FCF margin).
- Investors pay more for each dollar of Alkermes’s earnings: a P/E of 114.8x against 41.6x for Amneal Pharmaceuticals.
| Latest fiscal year | ALKS · FY25 | AMRX · FY25 |
|---|---|---|
| Size | ||
| Market cap | $7.6B | $6.7B |
| Revenue | $1.5B | $3.0B |
| Free cash flow | $480M | $270M |
| Net income | $242M | $72.1M |
| Growth | ||
| Revenue growth | −5.3% | 8.1% |
| 5-year growth | 7.3% | 8.7% |
| Share count change | −0.3% | 5.1% |
| Profitability | ||
| Gross margin | 86.7% | 36.9% |
| Operating margin | 17.2% | 13.1% |
| Net margin | 16.4% | 2.4% |
| FCF margin | 32.6% | 8.9% |
| Return on capital | — | 16.1% |
| Return on equity | 14.7% | — |
| Balance sheet | ||
| Net debt | — | $2.3B |
| Net debt / EBITDA | — | 3.8x |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | 114.8x | 41.6x |
| Piotroski F-score | — | 7 |
FY16
ALKS $746M
AMRX $1.0B
FY17
ALKS $903M
AMRX $1.0B
FY18
ALKS $1.1B
AMRX $1.7B
FY19
ALKS $1.2B
AMRX $1.6B
FY20
ALKS $1.0B
AMRX $2.0B
FY21
ALKS $1.2B
AMRX $2.1B
FY22
ALKS $1.1B
AMRX $2.2B
FY23
ALKS $1.7B
AMRX $2.4B
FY24
ALKS $1.6B
AMRX $2.8B
FY25
ALKS $1.5B
AMRX $3.0B
ALKS
AMRX
FY16
ALKS −28.0%
AMRX 28.0%
FY17
ALKS −16.4%
AMRX 23.7%
FY18
ALKS −9.1%
AMRX −1.2%
FY19
ALKS −15.0%
AMRX −15.3%
FY20
ALKS −10.8%
AMRX 4.6%
FY21
ALKS 8.3%
AMRX 7.3%
FY22
ALKS −0.6%
AMRX −4.3%
FY23
ALKS 24.9%
AMRX 8.5%
FY24
ALKS 27.0%
AMRX 8.9%
FY25
ALKS 17.2%
AMRX 13.1%
ALKS
AMRX
FY16
ALKS −$107M
AMRX −$7.7M
FY17
ALKS −$32.1M
AMRX $139M
FY18
ALKS $29.9M
AMRX $167M
FY19
ALKS −$18.9M
AMRX −$45.5M
FY20
ALKS $40.6M
AMRX $323M
FY21
ALKS $73.7M
AMRX $194M
FY22
ALKS −$17.2M
AMRX $18.7M
FY23
ALKS $353M
AMRX $302M
FY24
ALKS $406M
AMRX $243M
FY25
ALKS $480M
AMRX $270M
ALKS
AMRX
FY16
ALKS −15.5%
AMRX —
FY17
ALKS −11.4%
AMRX —
FY18
ALKS −8.0%
AMRX −0.7%
FY19
ALKS −15.9%
AMRX −6.3%
FY20
ALKS −11.6%
AMRX 2.5%
FY21
ALKS 10.8%
AMRX 3.4%
FY22
ALKS −0.6%
AMRX −2.6%
FY23
ALKS 57.2%
AMRX 6.2%
FY24
ALKS —
AMRX 8.5%
FY25
ALKS —
AMRX 16.1%
ALKS
AMRX
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.